Search

Apr 19, 2013 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on March 15th, 2013 at $8.97. In approximately 1 month, NPS Pharmaceuticals has returned [...]

Apr 12, 2013 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on March 15th, 2013 at $8.97. In approximately 4 weeks, NPS Pharmaceuticals has returned [...]

Apr 05, 2013 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on March 15th, 2013 at $8.97. In approximately 3 weeks, NPS Pharmaceuticals has returned [...]

LONDON, March 22, 2013 /PRNewswire/ -- Biotechnology companies are expected to face significant challenges in the near future due to rising costs related to the Affordable Care Act (ACA). Increasing [...]

Mar 20, 2013 (SmarTrend(R) Upgrades/Downgrades via COMTEX) -- NPS Pharmaceuticals (NASDAQ:NPSP) was downgraded from Buy to Hold at Brean Capital today. The stock closed yesterday at $9.88 on volume of [...]

Mar 20, 2013 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required [...]

M2 PRESSWIRE-March 20, 2013-BUYINS.NET: Market Maker Surveillance Report. NPSP, GAIA, DWCH, GST, EFUT, PRMW, Winning Stocks With Lowest Price Friction For Tuesday, March 19th 2013(C)1994-2013 M2 COMMUNICATIONS RDATE:20032013 BUYINS.NET / [...]

Byline: Zacks Equity Research Mar 20, 2013 (Zacks.com via COMTEX) -- NPS Pharmaceuticals, Inc. (NPSP) and Takeda Pharmaceutical Company Limited (TKPYY) recently amended their deal regarding a couple of drugs. [...]

ENPNewswire-March 20, 2013--TAKEDA -NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84(C)2013 ENPublishing - http://www.enpublishing.co.uk ENP Newswire - 20 [...]

Boston, Mar 19, 2013 (MidnightTrader via COMTEX) -- Top Healthcare Stocks JNJ -0.12% PFE -0.12% ABT +0.01% MRK +0.21% AMGN +0.90% Healthcare stocks are mixed this afternoon, with the NYSE [...]

Boston, Mar 19, 2013 (MidnightTrader via COMTEX) -- NPS Pharmaceuticals, Inc. (NPSP) has re-gained the full worldwide rights to teduglutide (Revestive) and recombinant human parathyroid hormone 1-84 (PTH 1-84) (Preotact). [...]

M2 PRESSWIRE-March 19, 2013-: NPS Pharmaceuticals and Takeda Revise Agreements and NPS Re-Gains Full Worldwide Rights to Teduglutide and Recombinant Human Parathyroid Hormone 1-84(C)1994-2013 M2 COMMUNICATIONS RDATE:19032013 BEDMINSTER, New Jersey [...]

Mar 19, 2013 (M2 PRESSWIRE via COMTEX) -- BEDMINSTER, New Jersey and Osaka, Japan -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and Takeda Pharmaceutical Company Limited (TSE: 4502, 'Takeda') announced today [...]

Mar 19, 2013 (M2 EQUITYBITES via COMTEX) -- Biopharmaceutical company NPS Pharmaceuticals Inc (Nasdaq:NPSP) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that NPS has re-gained the full worldwide [...]

Takeda to receive NPS common stock of $50 million and a potential future sales-based milestone payment Provides NPS with opportunity to establish global orphan specialty franchise NPS to host conference [...]

NPS Pharmaceuticals Inc (NPS) and Takeda Pharmaceutical Co Ltd (Takeda) announced that NPS has re-gained the full worldwide rights to teduglutide (trade name in Europe: Revestive) and recombinant human parathyroid [...]

BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Barclays Capital Global Healthcare Conference in Miami, Florida on Wednesday, March 13, 2013 at 11:15 a.m. ET. The [...]

BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, February 26, 2013 at 10:00 AM ET. [...]

Byline: Dennis Fitzgerald As the advisers in the $168.9 million agreement between handheld computer makers Palm Inc. and Handspring Inc. would quickly attest, there's no denying the importance of letting [...]

Shares of Enzon Pharmaceuticals Inc. - one of New Jersey's largest biotech firms - fell Thursday after the company lost its merger partner the night before. The Bridgewater-based company's shares [...]

Byline: Andrew Morse With its merger off, NPS Pharmaceuticals Inc. now has to figure out how to finance the development of its lead product and how to shepherd it through […]

Byline: Andrew Morse NPS Pharmaceuticals Inc. and Enzon Pharmaceuticals Inc. have called off their controversial $1.6 billion merger after the two companies failed to agree on a renegotiation of the […]

Byline: Matthew Wurtzel The largest U.S. deal announced this week was the merger of Gart Sports Co. of Englewood, Colo., and Sports Authority Inc. of Fort Lauderdale, Fla. The sporting [...]

One of New Jersey's largest biotechnology companies said Thursday it has agreed to merge with a sizable rival in a stock deal the firms valued at $1.6 billion. In what [...]

Byline: Andrew Morse NPS Pharmaceuticals Inc. and Enzon Pharmaceuticals Inc. said Thursday, Feb. 20, they had agreed to merge in an all-stock transaction valued at about $1.6 billion. NPS shareholders […]

BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco Wednesday, January 9, 2013 at 9:00 a.m. PT. The [...]

BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) will host a conference call to discuss its commercialization plan for Gattex, including the cost of therapy, today at 5:00 p.m. Eastern [...]

Dec 28, 2012 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on September 10th, 2012 at $8.16. In approximately 4 months, NPS Pharmaceuticals has returned [...]

Dec 28, 2012 (M2 EQUITYBITES via COMTEX) -- Biopharmaceutical company NPS Pharmaceuticals Inc (Nasdaq:NPSP) announced on Thursday the establishment of a patient-centric distribution and clinical service network for Gattex (Teduglutide [...]

Boston, Dec 27, 2012 (MidnightTrader via COMTEX) -- NPS Pharmaceuticals Inc. (NPSP) has established a distribution and clinical service network for Gattex for Injection, for subcutaneous use. The network is [...]

Boston, Dec 21, 2012 (MidnightTrader via COMTEX) -- NPS Pharmaceuticals, Inc. (NPSP) announced that the U.S. Food and Drug Administration has approved Gattex for Injection, for subcutaneous use for the [...]

NPS Pharmaceuticals Inc, a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, announced that the US Food and Drug Administration (FDA) has [...]

The US Food and Drug Administration has approved Gattex (teduglutide) to treat adults with short bowel syndrome (SBS) who need additional nutrition from intravenous feeding (parenteral nutrition). Gattex is an [...]

-- First major long-term treatment advance for adult SBS in nearly 40 years -- -- U.S. launch in first quarter of 2013 -- -- NPS Pharmaceuticals to host conference call [...]

Dec 20, 2012 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on September 10th, 2012 at $8.16. In approximately 3 months, NPS Pharmaceuticals has returned [...]

Dec 05, 2012 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on September 10th, 2012 at $8.16. In approximately 3 months, NPS Pharmaceuticals has returned [...]

-- Study available online in Gastroenterology -- BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, announced today that [...]

Nov 28, 2012 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for NPS Pharmaceuticals (NASDAQ:NPSP) on September 10th, 2012 at $8.16. In approximately 3 months, NPS Pharmaceuticals has returned [...]

BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 2012 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 4, 2012 at 10:10 a.m. ET. The presentation [...]

-- FDA Advisory Committee unanimously recommends approval of Gattex[R] (teduglutide) for adult patients with short bowel syndrome -- -- One out of seven patients has now achieved independence from PN/IV [...]

(EDGAR Online via COMTEX) -- -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act [...]

BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference in New York on Wednesday, November 14, 2012 at [...]

- Data presented at American College of Gastroenterology Annual Scientific Meeting - BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and [...]

US drug advisers on 16 Oct 2012 backed a drug to treat a rare and serious bowel disorder for which there is no long-term treatment available in the US. A [...]

-- Company also reports additional five patients achieved independence from PN/IV fluids in ongoing STEPS 2 study -- -- NPS to host conference call tomorrow at 8:30 AM ET -- [...]

BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced that NASDAQ has halted trading of the company's common [...]

Boston, Oct 15, 2012 (MidnightTrader via COMTEX) -- NPS Pharmaceuticals Inc. (NPSP) is down 5.5%, backing off earlier gains after announcing new findings from its phase 3 REPLACE study of [...]

-- Bone data from REPLACE along with results from eight-week RELAY study presented at American Society for Bone and Mineral Research Annual Meeting -- BEDMINSTER, N.J. -- NPS Pharmaceuticals, Inc. [...]